Get the latest news on Somaxon. Click any link to retrieve the press release in PDF format. (Adobe Acrobat Reader is required). If you don’t have Adobe Acrobat, download it for free from Adobe.
August 25, 2010 SOMAXON PHARMACEUTICALS ANNOUNCES SILENOR® CO-PROMOTION AGREEMENT WITH PROCTER & GAMBLE
SAN DIEGO, CA — August 25, 2010
— Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Somaxon and Procter & Gamble (NYSE: PG) have entered into a co-promotion agreement for Silenor® (doxepin), a newly-approved treatment for insomnia characterized by difficulty with sleep maintenance.
(.pdf).
August 11, 2010 SOMAXON PHARMACEUTICALS REPORTS SECOND QUARTER 2010 FINANCIAL RESULT
SAN DIEGO, CA — August 11, 2010
— Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.
(.pdf).
August 4, 2010 SOMAXON PHARMACEUTICALS TO REPORT SECOND QUARTER 2010 RESULTS AND CONDUCT CONFERENCE CALL ON WEDNESDAY, AUGUST 11
SAN DIEGO, CA — August 4, 2010
— Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will release its second quarter 2010 financial results on Wednesday, August 11, 2010 after the closing of the U.S. financial markets. The Company will also conduct a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and highlights of the second quarter 2010.
(.pdf).
July 29, 2010 SOMAXON PHARMACEUTICALS TO PRESENT AT THE BMO CAPITAL MARKETS 10TH ANNUAL FOCUS ON HEALTHCARE CONFERENCE
SAN DIEGO, CA — July 29, 2010
— Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Richard W. Pascoe, Somaxon's president and chief executive officer, will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference at The Sheraton New York Hotel and Towers in New York City on Thursday, August 5th at 10:45 a.m. Eastern Time.
(.pdf).
July 21, 2010 SOMAXON PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PHASE 3 CLINICAL TRIAL DATA FOR PUBLICATION IN SLEEP AND SLEEP MEDICINE
SAN DIEGO, CA — July 21, 2010
— Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the company's product Silenor® (doxepin) have been accepted for publication in peer-reviewed scientific journals.
(.pdf).
July 14, 2010 SOMAXON PHARMACEUTICALS ESTABLISHES SILENOR COMMERCIAL TEAM
SAN DIEGO, CA — July 14, 2010
— Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has established a commercial team to promote Silenor� (doxepin) for the treatment of insomnia characterized by difficulties with sleep maintenance.
(.pdf).
June 28, 2010 SOMAXON PHARMACEUTICALS ADDED TO RUSSELL 3000® INDEX, RUSSELL 2000® INDEX, RUSSELL GLOBAL® INDEX AND RUSSELL MICROCAP® INDEX
SAN DIEGO, CA — June 28, 2010
— Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the company's shares have been added to the broad-market Russell 3000® Index, the Russell 2000® Index, Russell Global Index and Russell Microcap® Index following Russell Investments' reconstitution of its comprehensive set of U.S. and global equity indexes after market close on June 25, according to an updated list of additions posted June 25 on www.russell.com.
(.pdf).
May 11, 2010 SOMAXON PHARMACEUTICALS REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS
SAN DIEGO, CA — May 11, 2010
— Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the first quarter ended March 31, 2010.
(.pdf).
May 3, 2010 SOMAXON PHARMACEUTICALS TO REPORT FIRST QUARTER 2010 RESULTS AND TO CONDUCT CONFERENCE CALL ON TUESDAY, MAY 11, 2010
SAN DIEGO, CA — May 3, 2010
— Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it will release its first quarter 2010 financial results on Tuesday, May 11, 2010 after the closing of the U.S. financial markets. The Company will also conduct a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and highlights of the first quarter 2010.
(.pdf).
April 12, 2010 SOMAXON PHARMACEUTICALS APPOINTS CHIEF FINANCIAL OFFICER AND ANNOUNCES SENIOR LEADERSHIP PROMOTIONS
SAN DIEGO, CA — April 12, 2010
— Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced the appointment of Tran B. Nguyen as Vice President and Chief Financial Officer. The company also announced other executive management team updates.
(.pdf).
March 31, 2010 SOMAXON ANNOUNCES COMPLETION OF PUBLIC OFFERING OF COMMON STOCK
SAN DIEGO, CA — March 31, 2010
— Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced the closing of its previously announced public offering of 6,900,000 shares of its common stock, including 900,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters, at a price to the public of $8.25 per share. The net proceeds from the sale of the shares, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $52.8 million.
(.pdf).
March 25, 2010 SOMAXON ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
SAN DIEGO, CA — March 25, 2010
— Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that it has priced an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.25 per share.
The net proceeds from the sale of the shares, after estimated underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $45.9 million.
The offering is expected to close on or about March 31, 2010, subject to customary closing conditions. (.pdf).
March 22, 2010 SOMAXON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
SAN DIEGO, CA — March 22, 2010
— Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that it is offering to sell
up to 4,000,000 shares of its common stock in an underwritten public offering.
Jefferies & Company, Inc. is acting as sole book-running manager in the
offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon
expects to grant the underwriters an option to purchase up to an additional
600,000 shares of common stock to cover overallotments of shares, if any. The
offering is subject to market conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual size or terms
of the offering (.pdf).
March 18, 2010, SOMAXON ANNOUNCES FDA APPROVAL OF SILENOR® (DOXEPIN)
FOR THE TREATMENT OF INSOMNIA - First and Only Prescription Sleep Aid to Provide a Full Night's Sleep Without Abuse Potential
Conference call scheduled today at 9:00 a.m. PT (12:00 p.m. ET); Simultaneous webcast at http://investors.somaxon.com/eventdetail.cfm
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance (.pdf).
March 18, 2010, SOMAXON REPORTS 2009 FULL YEAR FINANCIAL RESULTS - First and Only Prescription Sleep Aid to Provide a Full Night's Sleep Without Abuse Potential
Conference call scheduled today at 9:00 a.m. PT (12:00 p.m. ET); Simultaneous webcast at http://investors.somaxon.com/eventdetail.cfm
SAN DIEGO, CA –Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the fourth quarter and full year ended December 31, 2009 (.pdf).
January 27, 2010,
Somaxon Pharmaceuticals to Present
at the 12th Annual BIO CEO & Investor Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Richard W. Pascoe, Somaxon's president and chief executive officer, will present a company overview at the 12th Annual BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Monday, February 8th at 9:30 A.M. Eastern Time.
A live webcast of the presentation will be available in the Investor Relations section of the company's Web site under Event Scheduler at www.somaxon.com . The webcast will be archived and accessible for at least 14 days. (.pdf)
January 21, 2010, SOMAXON PROVIDES UPDATE ON NEW DRUG APPLICATION FOR
SILENOR® FOR THE TREATMENT OF INSOMNIA
Resubmission has been filed, with 2 month review cycle
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today provided an update on the status of its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia. (.pdf)
